Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a complex disorder characterized by vascular remodeling and a consequent increase in pulmonary vascular resistance. The histologic hallmarks of PAH include plexiform and neointimal lesions of the pulmonary arterioles, which are composed of dysregulated, apopt...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/16/12653 |
| _version_ | 1797584500336623616 |
|---|---|
| author | Soni Savai Pullamsetti Ravikumar Sitapara Robin Osterhout Astrid Weiss Laura L. Carter Lawrence S. Zisman Ralph Theo Schermuly |
| author_facet | Soni Savai Pullamsetti Ravikumar Sitapara Robin Osterhout Astrid Weiss Laura L. Carter Lawrence S. Zisman Ralph Theo Schermuly |
| author_sort | Soni Savai Pullamsetti |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is a complex disorder characterized by vascular remodeling and a consequent increase in pulmonary vascular resistance. The histologic hallmarks of PAH include plexiform and neointimal lesions of the pulmonary arterioles, which are composed of dysregulated, apoptosis-resistant endothelial cells and myofibroblasts. Platelet-derived growth factor receptors (PDGFR) α and β, colony stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor kit (c-KIT) are closely related kinases that have been implicated in PAH progression. In addition, emerging data indicate significant crosstalk between PDGF signaling and the bone morphogenetic protein receptor type 2 (BMPR2)/transforming growth factor β (TGFβ) receptor axis. This review will discuss the importance of the PDGFR-CSF1R-c-KIT signaling network in PAH pathogenesis, present evidence that the inhibition of all three nodes in this kinase network is a potential therapeutic approach for PAH, and highlight the therapeutic potential of seralutinib, currently in development for PAH, which targets these pathways. |
| first_indexed | 2024-03-10T23:52:31Z |
| format | Article |
| id | doaj.art-94cbad9b84124c57926e9f45ad69a230 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T23:52:31Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-94cbad9b84124c57926e9f45ad69a2302023-11-19T01:26:43ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-08-0124161265310.3390/ijms241612653Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial HypertensionSoni Savai Pullamsetti0Ravikumar Sitapara1Robin Osterhout2Astrid Weiss3Laura L. Carter4Lawrence S. Zisman5Ralph Theo Schermuly6Lung Vascular Epigenetics, Center for Infection and Genomics of the Lung (CIGL), Justus-Liebig-Universität Gießen, Aulweg 132, 35392 Giessen, GermanyGossamer Bio, Inc., San Diego, CA 92121, USAGossamer Bio, Inc., San Diego, CA 92121, USAUGMLC Pulmonale Pharmakotherapie, Biomedizinisches Forschungszentrum Seltersberg (BFS), Justus-Liebig-Universität Gießen, Schubertstraße 81, 35392 Giessen, GermanyGossamer Bio, Inc., San Diego, CA 92121, USAGossamer Bio, Inc., San Diego, CA 92121, USADepartment of Internal Medicine, Justus-Liebig-University Giessen, Aulweg 130, 35392 Giessen, GermanyPulmonary arterial hypertension (PAH) is a complex disorder characterized by vascular remodeling and a consequent increase in pulmonary vascular resistance. The histologic hallmarks of PAH include plexiform and neointimal lesions of the pulmonary arterioles, which are composed of dysregulated, apoptosis-resistant endothelial cells and myofibroblasts. Platelet-derived growth factor receptors (PDGFR) α and β, colony stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor kit (c-KIT) are closely related kinases that have been implicated in PAH progression. In addition, emerging data indicate significant crosstalk between PDGF signaling and the bone morphogenetic protein receptor type 2 (BMPR2)/transforming growth factor β (TGFβ) receptor axis. This review will discuss the importance of the PDGFR-CSF1R-c-KIT signaling network in PAH pathogenesis, present evidence that the inhibition of all three nodes in this kinase network is a potential therapeutic approach for PAH, and highlight the therapeutic potential of seralutinib, currently in development for PAH, which targets these pathways.https://www.mdpi.com/1422-0067/24/16/12653PDGFRc-KITCSF1RABLimatinibdasatinib |
| spellingShingle | Soni Savai Pullamsetti Ravikumar Sitapara Robin Osterhout Astrid Weiss Laura L. Carter Lawrence S. Zisman Ralph Theo Schermuly Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension International Journal of Molecular Sciences PDGFR c-KIT CSF1R ABL imatinib dasatinib |
| title | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension |
| title_full | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension |
| title_fullStr | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension |
| title_full_unstemmed | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension |
| title_short | Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension |
| title_sort | pharmacology and rationale for seralutinib in the treatment of pulmonary arterial hypertension |
| topic | PDGFR c-KIT CSF1R ABL imatinib dasatinib |
| url | https://www.mdpi.com/1422-0067/24/16/12653 |
| work_keys_str_mv | AT sonisavaipullamsetti pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT ravikumarsitapara pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT robinosterhout pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT astridweiss pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT lauralcarter pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT lawrenceszisman pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension AT ralphtheoschermuly pharmacologyandrationaleforseralutinibinthetreatmentofpulmonaryarterialhypertension |